Review on Targeting the DNA Damaging Pathway: PARPi and Beyond1
Optimizing the management of HER2-negative metastatic breast cancer in the era of PARP inhibitors—proceedings from breast cancer expert group meeting
Chinese Clinical Oncology
2020;
9
(5)
:61
.
(29 October 2020)
The management of BRCA1 and BRCA2 carriers in Singapore
Chinese Clinical Oncology
2020;
9
(5)
:62
.
(29 October 2020)
Breast cancer (BRCA) gene testing in ovarian cancer
Chinese Clinical Oncology
2020;
9
(5)
:63
.
(29 October 2020)
BReast CAncer (BRCA) gene mutations as an emerging biomarker for the treatment of gastrointestinal malignancies
Chinese Clinical Oncology
2020;
9
(5)
:64
.
(29 October 2020)
Germline mutations and prostate cancer: is it time to change treatment algorithms?
Chinese Clinical Oncology
2020;
9
(5)
:65
.
(29 October 2020)
BRCA sequencing of tumors: understanding its implications in the oncology community
Chinese Clinical Oncology
2020;
9
(5)
:66
.
(29 October 2020)
Multidisciplinary Sarcoma Tumor Board2
Multidisciplinary sarcoma tumor board: adolescent and young adult soft tissue sarcoma—myxoid liposarcoma and alveolar soft part sarcoma
Chinese Clinical Oncology
2020;
9
(5)
:67
.
(29 October 2020)
Original Article
Safety and efficacy of aprepitant as mono and combination therapy for the prevention of emetogenic chemotherapy-induced nausea and vomiting: post-marketing surveillance in China
Chinese Clinical Oncology
2020;
9
(5)
:68
.
(29 October 2020)
Review Article
Imaging and diagnostic approach of the adnexal mass: what the oncologist should know
Chinese Clinical Oncology
2020;
9
(5)
:69
.
(29 October 2020)
How far should we go in optimal cytoreductive surgery for ovarian cancer?
Chinese Clinical Oncology
2020;
9
(5)
:70
.
(29 October 2020)
Case Report
Breast carcinoma metastasis in a resected meningioma with early diagnosis of oligometastatic disease: a case report
Chinese Clinical Oncology
2020;
9
(5)
:71
.
(29 October 2020)
Erratum
Erratum to radical antegrade modular pancreatosplenectomy versus standard distal pancreatosplenectomy for pancreatic cancer, a dual-institutional analysis
Chinese Clinical Oncology
2020;
9
(5)
:72
.
(29 October 2020)
Disclosure:
1. The series “Targeting the DNA Damaging Pathway: PARPi and Beyond” was commissioned by the Editorial office, Chinese Clinical Oncology without any sponsorship or funding. Shaheenah Dawood served as the unpaid Guest Editor for the series.
2. The series “Multidisciplinary Sarcoma Tumor Board” was commissioned by the Editorial office, Chinese Clinical Oncology without any sponsorship or funding. William Tseng is serving as the unpaid Guest Editor for the series.
